Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

CDK Inhibitors Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent and Developments

P&S Market Research
Posted on: 11 Aug 17

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis

According to the research findings, most of the drug candidates of CDK inhibitors therapeutics pipeline are being developed to be administered by oral route.

USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.

Editor's Details

Vijay
P&S Market Research
www.psmarketresearch.com
+1-888-778-7886
vijaymishrapsmarket@gmail.com

Last updated on: 11/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.